Pharma, Biotech and Generics Industry News | The Pharmaletter
Oct 28, 2024 · India's BIRAC is propelling the country to global biotech leadership. 21 October 2024 As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth.
Pharma and Biotech News | The Pharmaletter
Nov 1, 2024 · The week in pharma: action, reaction and insight – week to November 1. US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co.
Pharmaceutical Industry News | The Pharmaletter
Oct 9, 2024 · CinFina Pharma, a CinRx portfolio developing a portfolio of treatment options for obesity, has presented positive top-line interim results from its Phase I single ascending dose (SAD) study of CIN-110 and final data from its multiple ascending dose (MAD) study of CIN-109. 4 November 2024.
Pharmaceutical Generics Industry News | The Pharmaletter
Sep 9, 2024 · API price plunge brings forth spectre of Chinese predatory pricing. A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024. More Generics News >.
Biotech Industry News | The Pharmaletter
Oct 28, 2024 · AbbVie punts $1.4 billion to buy early-stage Alzheimer’s drug developer Aliada. US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024.
FDA drug regulation and approval news | The Pharmaletter
6 days ago · Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024.
Pharma and Biotech Insights | The Pharmaletter
Oct 18, 2024 · India's BIRAC is propelling the country to global biotech leadership. As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024.
EMA drug regulation and approval news | The Pharmaletter
Oct 5, 2016 · Teva Prolia biosimilar accepted for review by FDA and EMA. Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024. Pharmaceutical.
Pharma Pricing, Policy and Regulatory News | The Pharmaletter
Oct 22, 2024 · The week in pharma: action, reaction and insight – week to November 1. US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co.
Pharma & Biotech Industry Analysis, from Thought Leaders
Sep 30, 2024 · F2G’s September $100m funding round provides the company with crucial funds to renavigate approval of its lead drug, olorofim. The substantial financing also highlights the paucity of novel antifungal products in the clinic.